Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, dlacebo-controlled, Phase 2, 12-Week treatment study with
a 10-Week Follow-up period to assess the efficacy and safety of Benralizumab (anti-IL5Rα) in
adult patients with chronic prurigo (BICPIC)